Loading
A trial tests engineered T cells that can target several tumor proteins, including TROP2. Its activity cannot be attributed to TROP2 targeting alone.
A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma. ClinicalTrials.gov record last updated 2025-09-03: recruiting. Enrollment is planned at 30 participants. Primary completion is estimated at 2028-01-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/